690
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)/PlGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin

, , , , &
Pages 179-187 | Received 11 Jul 2017, Accepted 27 Aug 2017, Published online: 11 Sep 2017

References

  • Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–683.
  • Knudsen UB, Kronborg CS, von Dadelszen P, et al. A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertens. 2012;2(1):8–15.
  • Khalil A, Muttukrishna S, Harrington K, et al. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One. 2008;3(7):e2766.
  • Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13–22.
  • Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50(1):137–142.
  • Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9–23.
  • Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125(7):911–919.
  • Sibiude J, Guibourdenche J, Dionne MD, et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One. 2012;7(11):e50208.
  • Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121–2131.
  • Cnossen JS, ter Riet G, Mol BW, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand. 2009;88(7):758–765.
  • NICE. PlGF-based testing to help diagnose suspected preeclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio). Diagnostics guidance [DG23]. London: NICE; 2010.
  • NICE. Hypertension in pregnancy. London: NICE; 2016.
  • Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791–1798.
  • Navaratnam K, Alfirevic A, Alfirevic Z. Low dose aspirin and pregnancy: how important is aspirin resistance? BJOG. Elsevier. 2016;123(9):1481–1487.
  • FitzGerald R, Pirmohamed M. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther. 2011;130(2):213–225.
  • Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167(15):1593–1599.
  • Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105(14):1650–1655.
  • Rey E, Rivard G-E. Is testing for aspirin response worthwhile in high-risk pregnancy? Eur J Obstet Gynecol. 2011;157(1):38–42.
  • Caron N, Rivard GE, Michon N, et al. Low-dose ASA response using the PFA-100 in women with high risk pregnancy. J Obstet Gynaecol Can. 2009;31(11):1022–1027.
  • Sullivan MH, Elder MG. Changes in platelet reactivity following aspirin treatment for pre-eclampsia. Br J Obstet Gynaecol. 1993;100(6):542–545.
  • Wójtowicz A, Undas A, Huras H, et al. Aspirin resistance may be associated with adverse pregnancy outcomes. Neuro Endocrinol Lett. 2011;32(3):334–339.
  • GROW. Bulk centile calculator: perinatal Institute; 2016 [cited 2017 08/09/16]; Bulk centile calculator. Available from: https://www.gestation.net/cc/about.htm.
  • Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188(1):177–182.
  • Benton SJ, Hu Y, Xie F, et al. Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction? Am J Obstet Gynecol. 2012;206(2):163.e1–163.e7.
  • Herraiz I, Dröge LA, Gómez-Montes E, et al. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol. 2014;124(2Pt1):265–273.
  • Gomez-Roig MD, Mazarico E, Sabria J, et al. Use of placental growth factor and uterine artery Doppler pulsatility index in pregnancies involving intrauterine fetal growth restriction or preeclampsia to predict perinatal outcomes. Gynecol Obstet Invest. 2015;80(2):99–105.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.